Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, BFF (PT009), BD ( PT008), SALBUTAMOL, Placebo MDI and empty TBH devices (only for training purposes)
AstraZeneca AB
Inadequately Controlled Asthma
1 trial -
TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Datopotamab deruxtecan
AstraZeneca AB
Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer
1 trial -
TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, CISPLATIN, PEMETREXED
AstraZeneca AB
Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.
1 trial -
TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
AstraZeneca AB
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
AstraZeneca AB
Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo
AstraZeneca AB
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.
1 trial -
TALAZOPARIB, TALAZOPARIB, TALAZOPARIB, Xtandi - 40 mg soft capsules, TALAZOPARIB
Pfizer Australia Pty Ltd
Metastatic Castration-resistant Prostate Cancer
1 trial -
TRUQAP 160 mg film-coated tablets, TRUQAP 200 mg film-coated tablets
AstraZeneca
HR+ / HER2- advanced breast cancer
1 trial -
Tesaglitazar
AstraZeneca
Type 2 Diabetes
1 trial -
Tesaglitazar 0.5 or 1 mg
AstraZeneca
Type 2 Diabetes
1 trial -
Tezepelumab
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
2 trials -
Tezepelumab
AstraZeneca
Asthma
2 trials -
Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe
AstraZeneca AB
Chronic obstructive pulmonary disease (COPD)
1 trial -
Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Tezspire 210 mg solution for injection in pre-filled syringe
AstraZeneca AB
Severe Asthma
1 trial -
Tezspire 210 mg solution for injection in pre-filled syringe
AstraZeneca AB
Chronic Rhinosinusitis with Nasal Polyposis
1 trial -
Tezspire 210 mg solution for injection in pre-filled syringe, Tezepelumab-placebo
AstraZeneca AB
Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus
1 trial -
Ticagrelor
AstraZeneca
Acute Coronary Syndrome
1 trial -
Ticagrelor 90 mg
AstraZeneca
Myocardial Infarction
1 trial -
Tozorakimab
AstraZeneca
Viral Lung Infection and Acute Respiratory Failure
1 trial -
Tozorakimab 1
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Tozorakimab, -, SALBUTAMOL, Tozorakimab-placebo
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Tozorakimab, Tozorakimab-placebo
AstraZeneca AB
Severe viral lung infections
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources